Aspirin and Undigestible Starch Don’t Protect Against Lynch Syndrome

Posted by Kate Murphy on December 29th, 2008
Tags: aspirin, fiber, Lynch syndrome

Neither daily aspirin or undigestible starch supplements reduced the risk for polyps and cancer for people with Lynch syndrome (also known as hereditary nonpolyposis colon cancer or HNPCC.)

Nearly 850 patients with identified Lynch syndrome were randomly assigned to receive aspirin, resistant starch, or placebos for up to four years.  After an average of two years, 141 developed either precancerous polyps or cancer (neoplasia). There was no difference in either overall neoplasia or advanced neoplasia whether patients took aspirin or resistant starch or received a placebo.

Henry Lynch, M.D., one of the study authors, said,

Aspirin has been used clinically for some time in patients at risk of Lynch syndrome, but our study shows that patients who take aspirin for this reason are simply wasting their time. The best protection continues to be an annual colonoscopy, beginning at age 25.

Dr. Lynch first described the inherited colorectal cancer syndrome now named for him.  People who inherit one of the genes associated with Lynch syndrome have a very high risk of getting colon cancer, often at a young age.  Inherited mutations reduce the possibility that damage to cell DNA will be repaired, leading to polyps and cancer.

John Burn M.D., who led the multinational study at 43 centers, and his team concluded,

The use of aspirin, resistant starch, or both for up to four years has no effect on the incidence of colorectal adenoma or carcinoma among carriers of the Lynch syndrome.

SOURCE: Burn et al., New England Journal of Medicine, Volume 359, Number 24, December 11, 2008.

Comments

marziyeh

March 1, 2009 at 12:55pm

hello
plz send me full text of this article
with thankx
m.babazadeh

Kate Murphy

March 1, 2009 at 5:07pm

We’re sorry. C3 does not have the full text of the article Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome in the December 11, 2008 issue of the New England Journal of Medicine. The lead author was John Burns,MD.

You might be able to find the NEJM in a medical library near you. Contact information for Dr. Burns is listed in the link to the article abstract.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe